With ongoing stagnation in its hepatitis C business, analysts are looking for Gilead Sciences Inc. to dip into business development activity as a way to return to growth, but the firm offered few clues during its July 25 second quarter earnings call, other than that it is looking outside virology.
HCV and HIV have made for a vigorous two-pillar antiviral business model at Gilead, but the still prosperous HCV franchise,...